Valuation: Attovia Therapeutics, Inc.

Market Cap 799M 714M 666M 605M 1.14B 77.28B 1.15B 8B 3.13B 39.3B 3B 2.93B 126B P/E 2026 *
-6.3x
P/E 2027 * -8.35x
Enterprise Value 420M 375M 350M 318M 599M 40.62B 603M 4.21B 1.64B 20.66B 1.58B 1.54B 66.41B EV / Sales 2026 *
900x
EV / Sales 2027 * -
Free-Float
91.15%
Yield 2026 *
-
Yield 2027 * -
1 day-6.54%
1 week-4.23%
Current month-4.23%
1 month-30.62%
1 week 16.33
Extreme 16.33
18.5
1 month 16.33
Extreme 16.33
28
Current year 16.15
Extreme 16.1501
28
1 year 16.15
Extreme 16.1501
28
3 years 16.15
Extreme 16.1501
28
5 years 16.15
Extreme 16.1501
28
10 years 16.15
Extreme 16.1501
28
Manager TitleAgeSince
Chief Tech/Sci/R&D Officer - 2022-12-15
Chief Tech/Sci/R&D Officer 61 2023-05-31
Chief Executive Officer 54 2023-03-31
Director TitleAgeSince
Director/Board Member 42 2023-05-31
Director/Board Member 54 2023-03-31
Chairman 64 2023-05-31
Date Insider Type Main position Quantity % Market Cap. Importance
8/6/26
Goldman Sachs & Co. LLC (Private Banking)
ConversionCompany 25,562,737 59.4081%
8/6/26 Conversion 1,865,710 4.3359%
8/6/26
Deep Track Capital LP
ConversionCompany 20,138,956 46.8032%
Change 5-day change 1-year change 3-year change Capi.($)
-6.11%-4.23% - - 799M
+4.16%+4.16%+49.37%+94.17% 74.69B
+0.46%-0.97%+23.51%+79.57% 58.81B
+0.17%+0.35%+6.85%+34.55% 48.45B
+0.14%-2.71%+328.81%+684.04% 42.84B
-0.81%-4.05%+28.42%+29.27% 42.79B
-0.21%-0.97%+6.08%+109.73% 41.25B
-0.11%+1.96%+9.19%+52.66% 31.13B
-2.07%+1.16%+35.00%+26.28% 30.28B
+0.13%-2.41%-9.55%-12.24% 24.05B
Average -0.50%-0.59%+53.08%+122.00% 39.51B
Weighted average by Cap. +0.57%-0.55%+55.98%+128.36%

Financials

2026 *2027 *
Net sales 467K 417K 389K 353K 665K 45.14M 670K 4.67M 1.83M 22.96M 1.75M 1.71M 73.81M -
Net income -83.44M -74.56M -69.56M -63.18M -119M -8.07B -120M -836M -327M -4.11B -313M -306M -13.2B -107M -95.73M -89.32M -81.13M -153M -10.36B -154M -1.07B -419M -5.27B -402M -394M -16.95B
Net Debt -379M -339M -316M -287M -540M -36.66B -544M -3.8B -1.48B -18.64B -1.42B -1.39B -59.93B -286M -256M -238M -217M -408M -27.68B -411M -2.87B -1.12B -14.08B -1.07B -1.05B -45.25B
Projected Income Statement - Annual - Attovia Therapeutics, Inc.
Logo Attovia Therapeutics, Inc.
Attovia Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing biotherapeutics for immune-mediated diseases with high unmet need. Its lead pipeline candidates target commercially validated pathways and are designed through its ATTOBODY biologics platform to deliver improved treatments relative to the standards of care. Its ATTOBODY platform uses an evolution-driven, high-throughput process which allows for discovery and creation of a high diversity of potential product candidates. It is developing a pipeline of novel biotherapeutics for the treatment of immune-mediated diseases. Its first two product candidates for its immune-dermatology franchise, ATTO-1310 and ATTO-2306, have the potential to treat patients suffering from pruritic and lesional diseases. Its third program, ATTO-1091, broadens its reach to other inflammatory diseases, such as IBD, a therapeutic area with substantial unmet need. ATTO-1310 is an ATTOBODY-based therapeutic targeting interleukin-31.
Employees
44
Date Price Change Volume
26-10-07 $16.45 -6.03% 370,791
26-10-06 $17.50 -2.75% 521,652
26-10-05 $18.00 +4.80% 455,958
26-10-02 $17.17 -3.49% 348,657
26-10-01 $17.79 +3.79% 530,815
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
5
Last Close Price
17.50USD
Average target price
42.20USD
Spread / Average Target
+141.14%

Quarterly revenue - Rate of surprise

Rate of surprise - Net sales - Quarterly - Attovia Therapeutics, Inc.
  1. Stock Market
  2. Stocks
  3. ATTO Stock